Signaling by the angiotensin-converting enzyme

Circulation Research

Volumn 98, Issue 7, 2006, Pages 887-896

  Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

ACE; Angiotensin II; Basic science; c Jun NH2 terminal kinase; Macrophages; Signal transduction

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOTENSIN II; BRADYKININ; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERASPENIDE; STRESS ACTIVATED PROTEIN KINASE; CALCIUM CHANNEL; DIPEPTIDYL CARBOXYPEPTIDASE;

BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; HYPERTENSION; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; CELL DIVISION; CYTOLOGY; GENETIC TRANSCRIPTION; HEART; HEART CONTRACTION; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCIUM CHANNELS; CELL DIVISION; HEART; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; PEPTIDYL-DIPEPTIDASE A; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 33646131838     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000217340.40936.53     Document Type: Review

References (112)

1. Xiao HD, Fuchs S, Frenzel K, Teng L, Bernstein KE. Circulating versus local angiotensin II in blood pressure control: lessons from tissue-specific expression of angiotensin-converting enzyme (ACE). Crit Rev Eukaryot Gene Expr. 2004;14:137-145.
2. Natesh R, Schwager SLU, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature. 2003;421:551-554.
3. Lattion AL, Soubrier F, Allegrini J, Hubert C, Corvol P, Alhenc-Gelas F. The testicular transcript of the angiotensin I-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme. FEBS Lett. 1989;252:99-104.
4. van Esch JHM, Tom B, Dive V, Batenburg WW, Georgiadis D, Yiotakis A, van Gool JMG, de Bruijn RJA, de Vries R, Danser AHJ. Selective angiotensin- converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension. 2005;45:120-125.
5. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31:912-917.
6. Junot C, Gonzales MF, Ezan E, Cotton J, Vazeux G, Michaud A, Azizi M, Vassiliou S, Yiotakis A, Corvol P, Dive V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther. 2001;297:606-611.
7. Kondoh G, Tojo H, Nakatani Y, Komazawa N, Murata C, Yamagata K, Maeda Y, Kinoshita T, Okabe M, Taguchi R, Takeda J. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat Med. 2005;11:160-166.
8. Leisle L, Parkin ET, Turner AJ, Hooper NM. Angiotensin-converting enzyme as a GPIase: a critical reevaluation. Nat Med. 2005;11:1139-1140.
9. Fuchs S, Frenzel K, Hubert C, Lyng R, Muller L, Michaud A, Xiao HD, Adams JW, Capecchi MR, Corvol P, Shur BD, Bernstein KE. Male fertility is dependent on dipeptidase activity of testis ACE. Nat Med. 2005;11:1140-1142.
10. Woodman ZL, Oppong SY, Cook S, Hooper NM, Schwager SL, Brandt WF, Ehlers MR, Sturrock ED. Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. Biochem J. 2000;347 Pt 3:711-718.
11. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, Clauser E. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem. 1991;266:5540-5546.
12. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A, Benetton G, Uslenghi E, Piazza A. Plasma activity and insertion/deletion polymorphism of angiotensin I- converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation. 1998;97:147-154.
13. Nagi DK, Foy CA, Mohamed-Ali V, Yudkin JS, Grant PJ, Knowler WC. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. Metabolism. 1998;47:622-626.
14. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A, Arveiler D, Cambou JP, Luc G. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation. 1994;90:669-676.
15. Oosterga M, Voors AA, de Kam PJ, Schunkert H, Pinto YM, Kingma JH, van Gilst WH. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation. 1997;95:2607-2609.
16. Kondoh G. Reply to 'Male fertility is dependent on dipeptidase activity of testis ACE.' Nat Med. 2005;11:1142-1143.
17. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994;94:978-984.
18. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC, Jr., Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR, Bernstein KE. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol. 2004;165:1019-1032.
19. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756-2767.
20. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, Ogihara T. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens. 1997;15:1295-1302.
21. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270-1277.
22. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
23. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens. 2004;22:1977-1982.
24. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76-81.
25. Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. Am Heart J. 2000;139:S15-S22.
26. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
27. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail. 1999;1:401-406.
28. Wu Q, Kuo HC, Deng GG. Serine proteases and cardiac function. Biochim Biophys Acta. 2005;1751:82-94.
29. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001;37:1056-1061.
30. Borland JA, Kelsall C, Yacoub MH, Chester AH. Expression, localization and function of ACE and chymase in normal and atherosclerotic human coronary arteries. Vascul Pharmacol. 2005;42:99-108.
31. Takai S, Jin D, Muramatsu M, Miyazaki M. Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci. 2004;25:518-522.
32. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell'Italia LJ, Feneley MP, Graham RM, Husain A. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest. 2004;114:112-120.
33. Wei CC, Tian B, Perry G, Meng QC, Chen YF, Oparil S, Dell'Italia LJ. Differential Ang II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol. 2002;282:H2254-H2258.
34. McDonald JE, Padmanabhan N, Petrie MC, Hillier C, Connell JM, McMurray JJ. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation. 2001;104:1805-1808.
35. Doggrell SA, Wanstall JC, Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol. 2005;83:123-130.
36. Fuchs S, Frenzel K, Xiao HD, Adams JW, Zhao H, Keshelava G, Teng L, Bernstein KE. Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. Curr Hypertens Rep. 2004;6:124-128.
37. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970;214:374-376.
38. Yang HY, Erdos EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971;177:291-300.
39. 2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension. 2000;36:132-136.
40. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
41. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
42. Busse R, Fleming I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci. 2003;24:24-29.
43. 2 kinin receptor gene knockout mice. Circ Res. 2001;88:1072-1079.
44. 2 receptor pathway. Circ Res. 2001;89:678-683.
45. Linz W, Jessen T, Becker RH, Schölkens BA, Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation. 1997;96:3164-3172.
46. Tom B, de Vries R, Saxena PR, Danser AHJ. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension. 2001;38:95-99.
47. Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA, Catelli de Carvalho MH. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension. 2001;37:703-709.
48. Danilczyk U, Penninger JM ACE2 in the heart and the kidney. Circ Res. 2006.
49. Danilczyk U, Eriksson U, Crackower MA, Penninger JM. A story of two ACEs. J Mol Med. 2003;81:227-234.
50. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
51. Benter TF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 1995;269:H313-H319.
52. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 1996;28:104-108.
53. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension. 2001;38:665-668.
54. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550.
55. Santos RAS, Silva ACS, Maric C, Silva DMR, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
56. Pinheiro SVB, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M, Santos RAS. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004;44:490-496.
57. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation. 2005;111:1806-1813.
58. Guigon M, Bonnet D. Inhibitory peptides in hematopoiesis. Exp Hematol. 1995;23:477-481.
59. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
60. Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, Yang XP. N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol. 2004;287:H2099-H2105.
61. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension. 2001;37:827-832.
62. Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb NE, Carretero OA. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension. 2004;43:229-236.
63. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl- lysyl-proline. J Clin Invest. 1996;97:839-844.
64. Peng H, Carretero OA, Brigstock DR, Oja-Tebbe N, Rhaleb NE. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension. 2003;42:1164-1170.
65. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE. Antifibrotic effect of Ac-SDKP and angiotensin- converting enzyme inhibition in hypertension. J Hypertens. 2004;22:593-603.
66. Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL, Rhaleb NE. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation. 2005;112:2436-2445.
67. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Mini Rev Med Chem. 2002;2:59-84.
68. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Ab by neprilysin. Science. 2001;292:1550-1552.
69. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease b-amyloid peptide is increased in mice deficient in endothelin- converting enzyme. J Biol Chem. 2003;278:2081-2084.
70. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (Ab): retards Ab aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001;276:47863-47868.
71. Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol. 1991;200:289-292.
72. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001;22:541-546.
73. Lendon CL, Thaker U, Harris JM, McDonagh AM, Lambert JC, Chartier-Harlin MC, Iwatsubo T, Pickering-Brown SM, Mann DM. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett. 2002;328:314-318.
74. Monastero R, Caldarella R, Mannino M, Cefalu AB, Lopez G, Noto D, Camarda C, Camarda LK, Notarbartolo A, Averna MR, Camarda R. Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. Neurosci Lett. 2002;335:147-149.
75. Hemming ML, Selkoe DJ. Amyloid b-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE Inhibitor. J Biol Chem. 2005;280:37644-37650.
76. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:126-129.
77. Busse R, Fleming I, Hecker M Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol. 1993;22(suppl 5):S31-S36.
78. Hecker M, Porsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 1994;111:238-244.
79. 1 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81:848-856.
80. 2 kinin receptor within the plasma membrane of native endothelial cells. Circulation. 1999;99:2034-2040.
81. 2 receptor. Hypertension. 1999;33:835-843.
82. Auch-Schwelk W, Bossaller C, Claus M, Graf K, Grafe M, Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res. 1993;27:312-317.
83. Danser AH, Tom B, de Vries R, Saxena PR. L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. Br J Pharmacol. 2000;131:195-202.
84. Minshall RD, Erdös EG, Vogel SM. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol. 1997;80:132A-136A.
85. 2 bradykinin receptor by ACE inhibitors. J Biol Chem. 2000;275:16110-16118.
86. 1 MF-2 smooth muscle cells. J Biol Chem. 1997;272:17858-17866.
87. 2 receptor in caveolae. J Cell Sci. 1998;111:917-928.
88. Schnitzer JE, McIntosh DP, Dvorak AM, Liu J, Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science. 1995;269:1435-1439.
89. Oh P, Schnitzer JE. Immunoisolation of caveolae with high affinity antibody binding to the oligomeric caveolin cage. J Biol Chem. 1999;274:23144-23154.
90. Marcic BM, Erdös EG. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther. 2000;294:605-612.
91. 2 kinin receptors. Hypertension. 2005;46:1368-1373.
92. Dendorfer A, Wolfrum S, Schafer U, Stewart JM, Inamura N, Dominiak P. Potentiation of the vascular response to kinins by inhibition of myocardial kininases. Hypertension. 2000;35:32-37.
93. Dendorfer A, Reibetamann S, Wolfrum S, Raasch W, Dominiak P. Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation. Hypertension. 2001;38:142-146.
94. 2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin. Can J Physiol Pharmacol. 2002;80:153-163.
95. Tom B, Dendorfer A, de Vries R, Saxena PR, Jan Danser AH. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol. 2002;137:276-284.
96. Kohlstedt K, Shoghi F, Müller-Esterl W, Busse R, Fleming I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res. 2002;91:749-756.
97. Santhamma KR, Sadhukhan R, Kinter M, Chattopadhyay S, McCue B, Sen I. Role of tyrosine phosphorylation in the regulation of cleavage secretion of angiotensin-converting enzyme. J Biol Chem. 2004;279:40227-40236.
98. Fleming I, Kohlstedt K, Busse R. New fACEs in the renin-angiotensin system. Physiology. 2005;20:91-95.
99. Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res. 2004;94:60-67.
100. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension. 2005;45:126-132.
101. Costerousse O, Allegrini J, Clozel J-P, Menard J, Alhenc-Gelas F. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther. 1998;284:1180-1187.
102. Boomsma F, de Bruyn JH, Derkx FH, Schalekamp MA. Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin Sci (Lond). 1981;60:491-498.
103. Kohno M, Yokokawa K, Minami M, Yasunari K, Maeda K, Kano H, Hanehira T, Yoshikawa J. Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Metabolism. 1999;48:1256-1259.
104. Stollberger C, Finsterer J. Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. Z Kardiol. 2003;92:721-729.
105. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004;43:573-577.
106. Kohlstedt K, Kellner R, Busse R, Fleming I. Signaling via the somatic angiotensin converting enzyme results in the phosphorylation of the non muscle myosin heavy chain IIA (MYH9). Mol Pharmacol. 2006;69:19-26.
107. Santhamma KR, Sen I. Specific cellular proteins associate with angiotensin-converting enzyme and regulate its intracellular transport and cleavage-secretion. J Biol Chem. 2000;275:23253-23258.
108. Hathaway GM, Traugh JA. Casein kinases-multipotential protein kinases. Curr Top Cell Regul. 1982;21:101-127.
109. Bren GD, Pennington KN, Paya CV. PKC-ζ-associated CK2 participates in the turnover of free IκBα. J Mol Biol. 2000;297:1245-1258.
110. Chattopadhyay S, Santhamma KR, Sengupta S, McCue B, Kinter M, Sen GC, Sen I. Calmodulin binds to the cytoplasmic domain of angiotensin-converting enzyme and regulates its phosphorylation and cleavage secretion. J Biol Chem. 2005;280:33847-33855.
111. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
112. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. J Am Med Assoc. 2001;286:1882-1885.